Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients

Department of Cardiology, Tel Aviv Medical Center, Israel.

OBJECTIVES: This study sought to establish the risk ratio for mortality associated with calcium antagonists in a large population of patients with chronic coronary artery disease. BACKGROUND: Recent reports have suggested that the use of short-acting nifedipine may cause an increase in overall mortality in patients with coronary artery disease and that a similar effect may be produced by other calcium antagonists, in particular those of the dihydropyridine type. METHODS: Mortality data were obtained for 11,575 patients screened for the Bezafibrate Infarction Prevention study (5,843 with and 5,732 without calcium antagonists) after a mean follow-up period of 3.2 years. RESULTS: There were 495 deaths (8.5%) in the calcium antagonist group compared with 410 in the control group (7.2%). The age-adjusted risk ratio for mortality was 1.08 (95% confidence interval [CI] 0.95 to 1.24). After adjustment for the differences between the groups in age and gender and the prevalence of previous myocardial infarction, angina pectoris, hypertension, New York Heart Association functional class, peripheral vascular disease, chronic obstructive pulmonary disease, diabetes and current smoking, the adjusted risk ratio declined to 0.97 (95% CI 0.84 to 1.11). After further adjustment for concomitant medication, the risk ratio was estimated at 0.94 (95% CI 0.82 to 1.08). CONCLUSIONS: The current analysis does not support the claim that calcium antagonist therapy in patients with chronic coronary artery disease, whether myocardial infarction survivors or others harbors an increased risk of mortality.

This article has been cited by other articles:

				M. Nishino, H.-J. Youn, D. Gheorghevici, C. Zellner, T. M. Chou, K. Sudhir, and R. F. Redberg Effect of Intracoronary Estradiol on Postischemic Microvascular Damage in a Porcine Model: A Myocardial Contrast Echocardiographic Study Angiology, November 1, 2003; 54(6): 701 - 709. [Abstract] [PDF]

				J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]

				J. W. Sear, S. J. Howell, Y. M. Sear, D. Yeates, M. Goldacre, and P. Foex Intercurrent drug therapy and perioperative cardiovascular mortality in elective and urgent/emergency surgical patients{{dagger}} Br. J. Anaesth., April 1, 2001; 86(4): 506 - 512. [Abstract] [Full Text] [PDF]

				M J A Williams, C J S Low, G T Wilkins, and R A H Stewart Randomised comparison of the effects of nicardipine and esmolol on coronary artery wall stress: implications for the risk of plaque rupture Heart, October 1, 2000; 84(4): 377 - 382. [Abstract] [Full Text]

				C. R. Meier, L. E. Derby, S. S. Jick, and H. Jick Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, and Breast Cancer Arch Intern Med, February 14, 2000; 160(3): 349 - 353. [Abstract] [Full Text] [PDF]

				J. G. Jollis, R. J. Simpson Jr, M. K. Chowdhury, W. E. Cascio, J. R. Crouse III, M. W. Massing, and S. C. Smith Jr Calcium Channel Blockers and Mortality in Elderly Patients With Myocardial Infarction Arch Intern Med, October 25, 1999; 159(19): 2341 - 2348. [Abstract] [Full Text] [PDF]

				J. Leor, H. Reicher-Reiss, U. Goldbourt, V. Boyko, S. Gottlieb, A. Battler, and S. Behar Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1920 - 1925. [Abstract] [Full Text] [PDF]

				V. M. Abascal, M. G. Larson, J. C. Evans, A. T. Blohm, K. Poli, and D. Levy Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Arch Intern Med, September 28, 1998; 158(17): 1882 - 1886. [Abstract] [Full Text]

				Calcium antagonists did not increase mortality in patients with coronary artery disease Evid. Based Med., February 1, 1997; 2(1): 29 - 29. [PDF]

				Calcium Channel Blockers Revisited Journal Watch Cardiology, September 1, 1996; 1996(901): 1 - 1. [Full Text]